BRIEF

on Soin Neuroscience

BIOTRONIK Neuro Acquires Patents from Soin Neuroscience

BIOTRONIK Neuro has acquired a portfolio of spinal cord stimulation patents from Soin Neuroscience, bolstering its technology for chronic pain management. The patents encompass innovations in waveform design, adaptive programming, and AI applications in neuromodulation. This acquisition follows a prior collaboration between the two companies, aiming to enhance the Prospera SCS System. BIOTRONIK Neuro will integrate these into its adaptive, data-driven platform, enhancing personalized therapy approaches.

Soin Neuroscience, led by Dr. Amol Soin, retains its independent operations and will continue its work in pain management technologies. BIOTRONIK sees this acquisition as reinforcing its commitment to advancing neuromodulation for chronic pain patients.

R. P.

Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all Soin Neuroscience news